| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 6.68 MB | Adobe PDF |
Advisor(s)
Abstract(s)
Mitochondrial gene therapy seems to be a valuable and promising strategy to treat mitochondrial disorders. The use of a therapeutic vector based on mitochondrial DNA, along with its affinity to the site of mitochondria, can be considered a powerful tool in the reestablishment of normal mitochondrial function. In line with this and for the first time, we successfully cloned the mitochondrial gene ND1 that was stably maintained in multicopy pCAG-GFP plasmid, which is used to transform E. coli. This mitochondrial-gene-based plasmid was encapsulated into nanoparticles. Furthermore, the functionalization of nanoparticles with polymers, such as cellulose or gelatin, enhances their overall properties and performance for gene therapy. The fluorescence arising from rhodamine nanoparticles in mitochondria and a fluorescence microscopy study show pCAG-GFP-ND1-based nanoparticles' cell internalization and mitochondria targeting. The quantification of GFP expression strongly supports this finding. This work highlights the viability of gene therapy based on mitochondrial DNA instigating further in vitro research and clinical translation.
Description
Keywords
Animals Cloning, Molecular DNA Mitochondrial Escherichia coli Fluorescence Gelatin Genes, Mitochondrial Genetic Therapy Genetic Vectors Green Fluorescent Proteins Humans Mice Mitochondria Nanoparticles Plasmids Polymers Rhodamines Transfection
Citation
Publisher
ACS Publications